Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma
- 15 September 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (18) , 5442-5447
Abstract
Purpose: Vaccination against human cancer is a promising therapeutic approach but the optimal antigen or antigens remain undefined. Cancer-testis antigens (CTA), a family of tumor-associated antigens, have both potent immunogenicity and restricted expression patterns in normal adult tissues, highly desirable characteristics for targets of anticancer vaccines. These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- CT7 (MAGE‐C1) antigen expression in normal and neoplastic tissuesInternational Journal of Cancer, 2002
- Identification of cancer/testis genes by database mining and mRNA expression analysisInternational Journal of Cancer, 2002
- Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesInternational Journal of Cancer, 2001
- Peptide Vaccination in Clinical OncologyOncology Research and Treatment, 2000
- Monoclonal antibody 57B stains tumor tissues that express geneMAGE-A4International Journal of Cancer, 2000
- CT10: A new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysisInternational Journal of Cancer, 2000
- Expression of MAGE-antigens in normal tissues and cancerInternational Journal of Cancer, 2000
- Cancer Tumor antigensCurrent Opinion in Immunology, 1997
- Expression of mage genes in transitional‐cell carcinomas of the urinary bladderInternational Journal of Cancer, 1995
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991